United Therapeutics: Ralinepag Is The Ultimate Defense Against Yutrepia (Rating Upgrade)
Source: SeekingAlpha
2026-03-11 06:53:36 ET
Overview
Although it has been two and a half years since my last write-up on United Therapeutics Corporation's ( UTHR ) stock, PAH is a space I’ve been following closely. So, when the company uncovered Phase 3 PAH results for a drug not named “treprostinil,” it piqued my interest....
Read the full article on Seeking Alpha
For further details see:
United Therapeutics: Ralinepag Is The Ultimate Defense Against Yutrepia (Rating Upgrade)
United Therapeutics Corporation
NASDAQ: UTHR
UTHR Trading
-0.59% G/L:
$540.97 Last:
225,542 Volume:
$530.15 Open:
UTHR Latest News
March 09, 2026 07:00:00 am
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
March 03, 2026 07:00:00 am
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
March 02, 2026 06:30:00 am
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
February 25, 2026 06:30:00 am
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
UTHR Stock Data
$20,237,032,096
38,621,769
0.2%
368
N/A
Biotechnology & Life Sciences
Healthcare
US
Silver Spring
